China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its in-house developed BCL2 inhibitor, ICP-248. This Category 1 innovative drug becomes the company’s fifth drug to reach clinical trials in the blood cancer field and its 13th overall.
Development Focus
InnoCare plans to develop ICP-248 for the treatment of malignant hematological tumors, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The drug works by specifically binding to BCL2, relieving the inhibition of the mitochondrial apoptosis pathway caused by BCL2 overexpression. This action releases and activates pro-apoptotic proteins, increases the permeability of the mitochondrial membrane, and releases cytochrome c. Additionally, ICP-248 activates the Caspase-mediated apoptosis cascade, restoring and promoting tumor cell apoptosis to exert anti-tumor effects.-Fineline Info & Tech
